Glaxo digests Zantac news well
The Investment Column
Friday 01 August 1997
For a start, though the US patent ran out a week ago, legal wrangles mean there are no generic versions yet on the market. This, however, will ultimately prove a temporary distraction. Glaxo is still bracing itself for Zantac to lose 80 per cent of its pounds 800m sales in two years when generics do finally pile in.
What should really make investors cheerful is that, heart drugs aside, and it may start in-licensing more products here, Glaxo probably has the strongest portfolio of new drugs in the UK.
The key figure in the interim results was that sales, excluding Zantac and the impact of sterling, rose 14 per cent - and an impressive 21 per cent in the massive US market. This was despite the patent expiry on Glaxo's second biggest drug, Zovirax, and sliding sales in old asthma drugs. New drugs launched before 1990 grew 50 per cent to pounds 1.3bn in the half year. The drivers were anti-Aids drugs - Glaxo's Epivir and Retrovir represent over half the world market in HIV drugs - and new asthma drugs like Serevent. Glaxo's focus on emerging markets is also paying off.
Of course, Glaxo's second half will be impacted by Zantac, plus rising expenditure on advertising and the addition of 600 sales people. This will mean a slight decline in earnings in 1997 and a flat result in 1998. But investors are prepared to look beyond that to see comfortable double- digit annual growth at a time when rivals SmithKline Beecham and Zeneca will be facing patent expiries of their own.
These thoughts are what has driven Glaxo's share price up 40 per cent this year. Yesterday's 38p fall to 1291.5p, reflects worries that margins will fall as spending rises. But new drugs need support and Glaxo is probably right to be investing in advertising and sales. The tobacco litigation settlement in the US, for example, is perfect timing to advertise Zyban, the group's new anti-smoking pill, on television.
The drugs sector generally will weaken as sterling falls, making cyclical and manufacturing stocks look more attractive. Glaxo itself looks set to be stuck on a forward p/e ratio of around 24 for the next two years. Looking beyond, however, with probably the freshest new drug pipeline in the UK sector, Glaxo has great potential to grow.
- 1 Venezuela Expo Tattoo 2015: Extreme body art from 'Vampire Woman' to 109mm earlobes
- 2 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 3 Ball pool for adults opens in London
- 4 Game of Thrones season 5 trailer: The first full-length look is here
- 5 Rashida Jones speaks out against male-centric porn saying 'women should have sex and feel good about it'
Mia Khalifa: Pornhub star claims Drake sent her 'cringeworthy' naked photos on Instagram
Boris Johnson claims porn-obsessed Islamic jihadists are 'literally w*****s'
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Putin opponent reveals Russian President's daughter's secret identity
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
King Abdullah dead: We can't afford not to hold Saudi Arabia's royals to account
iJobs Money & Business
£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...